Coaccioli S, Allegra A, Pennacchi M, Mattioli C, Ponteggia F, Brunelli A, Patucchi E, Puxeddu A
Department of Internal Medicine, Perugia University School of Medicine, S. Maria Hospital, Terni, Italy.
Int J Clin Pharmacol Res. 1998;18(1):39-50.
The clinical efficacy and the tolerance of galactosaminoglucuronoglycan sulphate (GGGS), administered both orally and intra-articularly were evaluated for the treatment of generalized and localized osteoarthritis (OA). The study included 154 patients: 52 treated orally with GGGS, observed during three periods of three consecutive months of therapy followed by eight weeks of withdrawal, 52 treated only with non-steroidal anti-inflammatory drugs (NSAIDs), and 50 patients treated two times in a year with a total of twelve (6 x 2) knee intra-articular weekly injections. The tolerance to GGGS was excellent, and the monitoring of the clinical measurements revealed a significant improvement of the articular data with a decreasing of NSAID's consumption.
评估了硫酸半乳糖氨基葡糖醛聚糖（GGGS）口服和关节内给药治疗全身性和局限性骨关节炎（OA）的临床疗效及耐受性。该研究纳入了154例患者：52例口服GGGS治疗，在连续三个月的三个治疗期内进行观察，随后停药八周；52例仅接受非甾体抗炎药（NSAIDs）治疗；50例患者每年接受两次共十二次（6×2）膝关节关节内每周注射治疗。GGGS的耐受性良好，临床测量监测显示关节数据有显著改善，且NSAIDs的消耗量减少。
